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Abstract
Background: High levels of death and morbidity worldwide caused by tuberculosis has stimulated efforts to develop a new
vaccine to replace BCG. A number of Mycobacterium tuberculosis (Mtb)-specific antigens have been synthesised as
recombinant subunit vaccines for clinical evaluation. Recently a fusion protein of TB antigen Ag85B combined with a second
immunodominant TB antigen TB10.4 was emulsified with a novel non-phospholipid-based liposomal adjuvant to produce a
new subunit vaccine, investigated here. Currently, there is no consensus as to whether or not long-term T cell memory
depends on a source of persisting antigen. To explore this and questions regarding lifespan, phenotype and cytokine
patterns of CD4 memory T cells, we developed an animal model in which vaccine-induced CD4 memory T cells could
transfer immunity to irradiated recipients.
Methodology/Principal Findings: The transfer of protective immunity using Ag85B-TB10.4-specific, CD45RB
low CD62L
low
CD4 T cells was assessed in sub-lethally irradiated recipients following challenge with live BCG, used here as a surrogate for
virulent Mtb. Donor T cells also carried an allotype marker allowing us to monitor numbers of antigen-specific, cytokine-
producing CD4 T cells in recipients. The results showed that both Ag85B-TB10.4 and BCG vaccination induced immunity
that could be transferred with a single injection of 3610
6 CD4 T cells. Ten times fewer numbers of CD4 T cells (0.3610
6) from
donors immunised with Ag85B-TB10.4 vaccine alone, transferred equivalent protection. CD4 T cells from donors primed by
BCG and boosted with the vaccine similarly transferred protective immunity. When BCG challenge was delayed for 1 or 2
months after transfer (a test of memory T cell survival) recipients remained protected. Importantly, recipients that contained
persisting antigen, either live BCG or inert vaccine, showed significantly higher levels of protection (p,0.01). Overall the
numbers of IFN-c-producing CD4 T cells were poorly correlated with levels of protection.
Conclusions/Significance: The Ag85B-TB10.4 vaccine, with or without BCG-priming, generated TB-specific CD4 T cells that
transferred protective immunity in mice challenged with BCG. The level of protection was enhanced in recipients containing
a residual source of specific antigen that could be either viable or inert.
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Introduction
Tuberculosis remains one of the world’s leading causes of
mortality and morbidity [1] despite the widespread use of the
BCG vaccine (Mycobacterium bovis, bacille Calmette-Gue ´rin). The
BCG vaccine confers protection during childhood [2] and in some
populations was found to have an efficacy of about 50% for up to
60 years[3]. Despite the beneficial effects, BCG vaccination does
not prevent substantial problems with pulmonary disease in the
adult population, especially in many developing countries [1].
There is an urgent need for a new vaccine. As a result of
technological advances, increases in funding and heightened
interest within the scientific community, there are a number of
candidate vaccines in various stages of clinical trials [4]. The
current candidate vaccines are broadly divided into live myco-
bacterium-based preparations, viral vectors or synthetic subunit
vaccines. One strategy for developing new live vaccines is to
introduce highly immunogenic, but non-pathogenic, epitopes from
Mycobacterium tuberculosis (Mtb) into the BCG genome or alterna-
tively to use a mutated Mtb in which at least two virulence genes
have been altered so as to render the microorganism harmless [5].
Another option is to express Mtb antigens in the modified vaccinia
virus Ankara (MVA) as a vaccine to boost subjects previously
immunised with BCG [6]. The third approach aims to develop
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be combined with novel adjuvant systems. The present study is
concerned with the latter type of vaccine.
A new vaccine strategy will only replace BCG when it is shown
that it exceeds the degree of protection and safety currently
provided by BCG. In the immediate future it is likely that any new
vaccine, especially subunit/vector vaccines, will be used to
augment the BCG-induced immune response. Attempts to boost
BCG-generated immunity with a second dose of BCG have failed
in both human trials and animal models [7,8]. The reasons for this
are not fully understood [1]. A heterologous prime/boost
immunisation procedure – BCG followed by a subunit vaccine –
is currently the favoured strategy to overcome the limitations of
the BCG vaccine.
Recently, recombinant Ag85B was combined with a second
Mtb-specific antigen TB10.4 [9,10] that is strongly recognised by T
cells from both BCG-vaccinated and TB patients [9]. A fusion
protein consisting of Ag85B and TB10.4 was therefore produced
and evaluated as a potential tuberculosis subunit vaccine [11]. It
was shown that Ag85B-TB10.4, when combined with a cationic
liposome adjuvant, induced a powerful cell-mediated response
[12], IFN-c producing CD4 T cells and protective immunity in
mice challenged with Mtb [13].
It is often assumed that immunological memory depends on
populations of memory CD4 T cells that are long-lived. This
assumption was questioned by adoptive transfer experiments,
reported several decades ago, that observed a rapid loss of memory
in recipients that were not challenged immediately with specific
antigen [14]. It has been argued that long-lived immunological
memory depends on a source of persisting antigen [15,16]. This
issue remains unresolved and has important implications for
vaccine development.
The present paper describes an experimental model that could
assist in evaluating immunological memory induced by candidate
vaccines. The study showed that protective immunity against a
BCG challenge was adoptively transferred with a subset of CD4 T
cells primed by BCG and boosted with the candidate vaccine
Ag85B-TB10.4. In addition, the investigation showed that




All animals were handled in strict accordance with good animal
practice as defined by the UK Animal (Scientific Procedures) Act
1986. All animal work was approved by the University of
Manchester Ethics Committee.
Animals
B6 (C57BL6J, CD45.2) mice were purchased from Charles
River, Manston, UK. A colony of the congenic strain B6.SJL
(C57BL6Ly5.1, CD45.1) was established in SPF (specific patho-
gen-free) conditions from breeding pairs supplied by Charles
River. Both strains were maintained under conventional husband-
ry in the Biological Services Unit of the University of Manchester.
Mice used as recipients were given a sub-lethal dose (7Gy) of
gamma irradiation delivered by an industrial X-ray tube, model
MXR-320/26, at a dose rate of 0.76 Gy/min.
Antigens and Adjuvants
The Danish 1331 strain of BCG was stored at 280uC and
thawed before injection. The candidate subunit vaccine Ag85B-
TB10.4, is a recombinant fusion protein composed of two antigens
from Mtb (Ag85B-TB10.4) [11] that are expressed by BCG. The
adjuvant CAF01 (dimethyl dioctadecyl ammonium bromide/
trehalose 6,69-dibehenate) [12,17] was prepared by the lipid film
method previously described [12] and stored at 4uC as a stable
solution. The vaccine was prepared just before use. Each dose
contained 2 mg of antigen mixed with 0.2 ml of adjuvant (250 mg
DDA and 50 mg TDB).
Immunisations
Mice were antigen-primed by injecting BCG or Ag85B-TB10.4
subcutaneously (s.c.) in both flanks, s.c. on the back of the neck and
intraperitoneally (i.p.). A dose of 5610
4 CFUs BCG was divided
between the different sites. For Ag85B-TB10.4 priming, mice
received 3 injections 2 weeks apart. BCG immunised mice were
boosted by injecting BCG or by distributing 2 mg Ag85B-TB10.4
combined with adjuvant between the same sites 2 mo after BCG
priming.
Adoptive Transfer
Immunised mice were killed, spleens and lymph nodes
(mesenteric, inguinal, and auxiliary) removed, teased apart with
forceps and filtered through a nylon monofilament mesh filter.
Splenic red blood cells were removed by layering the cell
suspension onto Histopaque (Sigma, Poole, UK) followed by
centrifugation. Cells remaining at the interface were recovered,
washed with PBS/FCS (phosphate buffered saline/2% foetal calf
serum), pooled and viable cells counted using an electronic Scharfe
CASY1 counter. Cells were stained for 30 min on ice with a
cocktail of the following rat anti-mouse mAbs (clone in
parentheses): CD45RB (16A), CD8 (53-6.7), CD19 (1D3), MHC
II (M5/114.15.2), F4-80 all from BD Biosciences UK and CD34
(MEC14.7) from Serotec Ltd, Oxford, UK. A sample of stained
cells was removed and incubated with FITC goat anti-rat IgG for
analysis before depletion. Goat anti-rat IgG BiomagH beads
(Metachem Diagnostics Ltd, Piddington, UK) were washed, mixed
with the cells at a concentration of 2 mls of beads per 10
8 cells and
incubated with occasional re-suspension for 30 min on ice. The
cell/bead suspension was placed on a strong magnet and the
ferrous beads with cells attached were removed by magnetic
adhesion. The cells that remained in suspension were recovered
and washed twice with PBS/FCS. The cells were counted, a
sample stained to assess the purity of the separation (as shown in
Fig. 1C) and the concentration adjusted for injection. Control
CD4 T cells were purified from naı ¨ve mice as described above but
without the addition of mAb CD45RB. Cells were analysed by
flow cytometry (FACSCalibur, BD, Cowley, UK) using Cell
Quest-Pro software. All cell populations were injected i.v.
BCG Protection Assay
Mice were injected i.v. in the lateral tail vein with 5610
4 BCG
in 0.2 ml to assess the ability of recipients to eliminate the
microorganism. Three weeks after injection spleens were removed,
weighed and a fraction removed for cytokine and flow cytometric
analysis. The remaining tissue was stored frozen to determine the
number of surviving BCG at a later time. Frozen spleens were
thawed, macerated on stainless-steel mesh, serially diluted, plated
onto Middlebrook 7H11 agar and incubated for 18 to 21 days at
37uC. Colonies of BCG were counted and the results scored as
CFU/whole spleen.
Intracellular Cytokine (ICC) Analysis
Spleen cells (5610
6/ml) were cultured overnight in RPMI plus
2% FCS at 37uC with or without 5 mg/ml of Ag85B-TB10.4.
CD4 T Cells Transfer Immunity
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Cells were washed, stained for CD4 (GK1.5) and donor CD45.1
(A20) or host CD45.2 (104) origin. The cells were washed, fixed
with 4% paraformaldehyde and stained with anti-IFN-c in 0.1%
Saponin. Cells were analysed by flow cytometry.
Statistical Analyses
Differences between means were assessed using Student’s t test.
Results
Adoptive Transfer of Primed CD4 T Cells Protects against
BCG Challenge
To examine the protective efficacy of vaccine-induced CD4 T cells,
an adoptive transfer model was developed as illustrated in Fig. 1A.
Donor B6.SJL mice were immunised with BCG and boosted 2 mo
later with BCG or Ag85B-TB10.4. Previous experience suggested that
antigen-primed CD4 T cells could be concentrated in the CD45RB
low
subset [18]. Spleen and lymph node cells, enriched for CD4T cells
(Fig. 1B),were depleted of the CD45RB
high population and the purified
CD45RB
low CD4 T cells (Fig. 1C) transferred i.v. to sub-lethally
irradiated recipients. The day after cell transfer, recipients were
challenged i.v. with live BCG and the spleen assessed 21 days later for a
reduction in BCG CFU. Since immunity to Mtb has been correlated
with a Th1 IFN-c response, spleen cell were stimulated in vitro with
Ag85B-TB10.4 antigen and stained for intracellular cytokine (ICC)
IFN-c. Following transfer, allotype-marked CD45.1 donor T cells were
identified in recipients by FACS (Fig. 1D), electronically gated and
examined for ICC IFN-c (Fig. 1E).
The kinetics of the antigen-specific CD4 T cells was studied in
BCG-primed mice that were boosted in vivo with Ag85G-TB10.4.
Fig. 2 shows the percentage of ICC IFN-c
+ CD4 T cells at various
times after boost. The response reached its maximum by day 7 and
this time point was used for collecting CD4 T cells in subsequent
experiments.
Initially we asked whether CD45RB
low CD4 T cells from
donors that were primed with BCG and boosted with BCG could
protect irradiated recipients against a live BCG challenge (Fig. 3A).
Both high (3610
6) and low (0.3610
6) doses of CD45RB
low CD4 T
cells were transferred. Significant protection (p,0.01) was
transferred with the high dose of primed CD4 T cells but not
the low dose (Fig. 3B). Nor was any protection transferred with a
high dose of unprimed naive CD4 T cells. Donor T cells were also
examined for the number of Ag85B-TB10.4-specific IFN-c
+ T
cells by ICC staining (Fig. 3C). By necessity the cytokine levels
were measured 3 weeks after bacterial challenge during the
ongoing elimination of the BCG infection. Curiously, the number
of antigen-specific IFN-c
+ CD4 T cells did not correlate with the
level of protection. To assess the effectiveness of the recombinant
vaccine in the absence of BCG, CD45RB
low CD4 T cells were
purified from donors immunised with Ag85B-TB10.4 and boosted
with Ag85B-TB10.4 (Fig. 3D). Significant protection was trans-
ferred with both 3610
6 – almost a log reduction (p,0.01) – and
ten-fold fewer (0.3610
6) Ag85B-TB10.4-primed CD4 T cells
(p,0.05) (Fig. 3E). Numbers of IFN-c
+ donor CD4 T cells were
highest in those recipients that showed protective immunity,
however, there were also significant numbers of cytokine-
producing cells in mice receiving naı ¨ve T cells where there was
no immunity (Fig. 3F).
BCG/Ag85B-TB10.4 (Prime/Boost) CD4 T Cells Transfer
Long-Lived Immunity
Since BCG vaccination has been used worldwide, any new
vaccine would need to provide protection in individuals previously
immunised with BCG. Therefore, CD4 T cells were assessed in
BCG-primed mice boosted with Ag85B-TB10.4. CD45RB
low
CD4 T cells were purified from BCG-primed/Ag85B-TB10.4-
boosted donors and transferred to irradiated recipients. In
addition, we wanted to assess whether the antigen-specific T cells
Figure 1. The development of an adoptive transfer model to
evaluate Mtb-specific CD4 T cells. (A) Donor mice (B6.SJL, CD45.1)
injected with BCG 2 mo before were boosted with Ag85B-TB10.4 and
killed 7 days later. Spleen and lymph nodes were removed, depleted of
B cells, CD8 T cells and macrophages. A representative profile of the
resulting CD4 T cell population stained for CD45RB is shown (B). CD4 T
cells were also depleted of CD45RB
high cells and injected into recipients
on day 0 (d 0). A representative profile of CD45RB
low CD4 T cells used
for adoptive transfer is shown (C). One day after transfer, irradiated
recipients (X-rad) were challenged i.v. with live BCG, killed 3 weeks later
(d 22) and spleens tested for a reduction in BCG numbers (Protection
assay, CFUs/spleen). An aliquot of spleen cells was cultured overnight in
the presence of Ag85B-TB10.4 antigen and stained for ICC IFN-c. Donor-
derived CD4 T cells (CD4
+ CD45.1
+) were gated in R1 (D) and analysed
for IFN-c positive cells (E). The donor-derived CD45.1
+ CD4
2 cells in
profile D (upper left quadrant) were predominantly contaminating B
cells. Numbers in the representative profiles are the percentage of
events in the quadrant.
doi:10.1371/journal.pone.0008272.g001
Figure 2. Kinetics of the antigen-specific CD4 T cell response in
BCG-immunised mice after a boost with Ag85B-TB10.4. Mice
were killed at selected days following antigen injection and spleen cells
analysed for ICC IFN-c. Results are the net percentage of IFN-c
+ CD4 T
cells stimulated in the presence of Ag85B-TB10.4 after subtraction of
the response without antigen. The results were pooled from 8
experiments. Each point represents the mean+SD of 3 or 4 mice,
except day 3, n=2.
doi:10.1371/journal.pone.0008272.g002
CD4 T Cells Transfer Immunity
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immunological memory. Hence, recipient mice were challenged
immediately after transfer (d 1) or after a delay of 2 mo (Fig. 4A, d
56). The results showed that CD4 T cells from BCG primed/
Ag85B-TB10.4 boosted donors (Pr/Boost) transferred significant
protection (p,0.01) to the BCG challenge administered immedi-
ately after transfer (Fig. 4B). To determine whether immunological
memory persisted, CD45RB
low CD4 T cells from BCG/Ag85B-
TB10.4 (Pr/Boost) donors were injected into irradiated recipients
and the BCG challenge delayed for 8 weeks (Fig. 4A). Recipients
in which the BCG challenge was delayed (Fig. 4B, d 56) remained
protected (p,0.01) confirming the continued survival of CD4 T
cells responsible for immunity. The level of protection was similar
to that in recipients challenged immediately after transfer
Figure 3. CD4 T cells specific for BCG or for Ag85B-TB10.4 transfer protective immunity. (A) CD45RB
low CD4 T cells were purified from
donors primed and boosted with BCG (Pr/Boost) and injected (3610
6 or 0.3610
6) into irradiated recipients (B, C). Control recipients received 3610
6
unprimed (Naı ¨ve) CD4 T cells or no cells (None). (D) CD45RB
low CD4 T cells were purified from donors primed with Ag85B-TB10.4 and boosted with
Ag85B-TB10.4 and 3610
6 or 0.3610
6 T cells injected into irradiated recipients. Control recipients received 3610
6 unprimed (Naı ¨ve) CD4 T cells or no
cells (None). All recipients in experiments A and D were challenged i.v. with BCG the day after transfer, killed 3 weeks later and assayed for BCG CFU/
spleen (B, E). Each point represents a single recipient. Donor-derived splenic CD4 T cells stimulated in vitro with Ag85B-TB10.4 were stained for
intracellular cytokine (ICC) IFN-c (C, F). The results were from single experiments. Horizontal bars or histograms + SD are means of 4 recipients/group.
*p ,0.05; ** p,0.01.
doi:10.1371/journal.pone.0008272.g003
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groups challenged on d 1 or d 56 (Fig. 4B). The experiment was
repeated with the same result (data not shown). Despite the long-
lived protection, there were significantly more (p,0.01) IFN-c
producing CD4 T cells detected in the spleen of recipients
challenged immediately following T cell transfer than in recipients
in which the challenge was delayed (Fig. 4C).
It is known that a lymphopenic environment such as that
induced following irradiation will enhance the survival and
expansion of the donor T cell population [19,20]. Therefore, as
an additional test of transferred immunity, CD45RB
low CD4 T
cells were injected into normal non-irradiated instead of irradiated
hosts. CD4 T cells from BCG/Ag85B-TB10.4 (Pr/Boost) donors
successfully transferred immunity to non-irradiated recipients
although, as expected, the level of protection was lower (log
CFU/spleen: Pr/Boost, 3.5960.02; No cells, 3.8860.11; p,0.05).
Persisting Antigen Enhances Protection
The role of residual antigen in maintaining immunological
memory remains controversial. We explored the influence of
antigen in the adoptive transfer model and asked whether
protective immunity was prolonged or shortened by the presence
of persisting antigen. To generate a source of residual antigen,
recipient mice were pre-injected (Fig. 5A, d -28) with either BCG
or Ag85B-TB10.4 and irradiated 4 weeks later, immediately prior
to cell transfer. Irradiation destroys the host’s own immune
response leaving behind a potential source of residual antigen. The
object was to compare Ag85B-TB10.4, a non-viable antigen, with
live BCG as a source of persisting antigen. As in the previous
experiment recipient mice received BCG/Ag85B-TB10.4 (Pr/
Boost) CD45RB
low CD4 T cells (Fig. 5B, solid symbols) and the
BCG challenge was delayed, in this case, for one month (Fig. 5A, d
28). A control group containing residual BCG (i.e. injected with
BCG and irradiated 4 weeks later) received naı ¨ve instead of
primed CD4 T cells (Fig. 5B, open symbols). The protection in
recipients with persisting antigen, both BCG and Ag85B-TB10.4,
was significantly increased (p,0.01) compared with that seen in
antigen-free recipients or in recipients that received naı ¨ve CD4 T
cells (Fig. 5B). A second experiment in which BCG was the source
of persisting antigen gave a similar result (data not shown). These
observations suggested that persisting antigen augmented the
protective immunity transferred by Mtb-specific CD4 T cells.
Discussion
The development of a new vaccine to supplement or replace
BCG is an international priority. To make the investigation of
vaccine-induced immunological memory to TB more accessible, we
wanted to establish an animal model suitable for laboratories
without class III (P3) containment facilities. Hence, we opted to
challenge recipients with live BCG rather than Mtb. Aside from the
clear difference in virulence, Mtb and BCG are very similar – both
are intracellular pathogens controlled predominantly by CD4 T
cells. In the more advanced stages of infection, Mtb appears to
induce a subset of CD8 T cells not seen after BCG vaccination [21],
but the role of these CD8 T cells in protection has never been
formally demonstrated. In the first stages of infection (the focus of
the present study), it is clear that both BCG and Mtb are controlled
byCD4T cells.Furthermore,the new recombinantvaccine Ag85B-
TB10.4 used in the present investigation expresses two immuno-
dominant antigens common to both BCG and Mtb. This vaccine
hasbeenshown to induce protective immunity in mice infected with
Mtb [11]. Hence, BCG should serve at this stage as a reliable
surrogate for Mtb challenge.
Previous studies established that antigen-specific CD4 T cells
become concentrated in a small subset of CD4 T cells identified by




low [22,23]. This subset represents
,10% of the CD4 T cell population and may be routinely purified
for adoptive transfer [18,24]. An allotype marker was used to allow
identification of donor T cells in recipients several months after
transfer to irradiated recipients. Following sub-lethal irradiation
the lymphocyte population of the host becomes temporarily
destroyed, creating a lymphopenic environment and initiating
Figure 4. Protective immunity persists for at least 8 weeks following transfer of prime/boost CD4 T cells. (A) CD45RB
low CD4 T cells
(3610
6) from donors primed with BCG and boosted with Ag85B-TB10.4 (Pr/Boost) or 3610
6 CD4 T cells from unprimed donors (Naı ¨ve) or no cells
(None) were transferred to irradiated recipients and challenged with BCG immediately (d 1) or 8 weeks later (d 56) (B, C). Three weeks after challenge
spleen cells were assayed for BCG CFUs (B) and ICC IFN-c
+ donor CD4 T cells (C). The results are from one experiment. Each point represents a single
recipient. Horizontal bars or histograms + SD are means of 4 recipients/group. ** p,0.01.
doi:10.1371/journal.pone.0008272.g004
CD4 T Cells Transfer Immunity
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engraftment.
Protective immunity to BCG challenge was successfully
transferred with CD45RB
low CD4 T cells from BCG/BCG and
BCG/Ag85B-TB10.4, prime/boost donors. The number of CFU/
spleen was consistently reduced by approximately a half-log. The
same number of CD4 T cells (3610
6) from donors that were
immunised exclusively with Ag85B-TB10.4 (primed and boosted
with Ag85B-TB10.4), transferred a greater level of protective
immunity (,1-log reduction in CFU). Furthermore, significant
protection was also transferred by one-tenth this number (0.3610
6)
of the CD4 T cells.
The apparent difference in protection using T cells from mice
immunised with BCG or solely with Ag85B-TB10.4 was
unexpected and suggests there could be quantitative differences
in the number of antigen-specific T cells transferred and/or
qualitative differences. A recent study from our laboratory
analysing CD44
high CD4 T cells from C57BL/6 mice immunized
with BCG was compared with those from mice immunised with a
subunit vaccine (Ag85B-ESAT-6) [13]. The latter is very similar to
the one used here; both recombinant vaccines were combined with
the same CAF01 adjuvant. In mice immunised with Ag85B-
ESAT-6 compared with BCG there were significant differences in
the type of multifunctional T cells (i.e. those producing more than
one of the cytokines IFN-c/IL-2/TNFa) present in mice
immunised more than 10 months earlier. CD4 T cells from these
mice (analogous to Ag85B-TB10.4/Ag85B-TB10.4 prime/boost
T cells used here) were predominantly of the triple- (,60%) and
double-producing IL-2
+/TNFa
+ type (,25%) with negligible
levels of single IFN-c-producing T cells. In contrast, T cells from
mice immunised with BCG and stimulated with the BCG extract
PPD (purified protein derivative) (T cells similar to that from
BCG/BCG prime/boost donors used here) had far fewer triple-
producing T cells (,35%), a different type of double-producing
(,35% INF-c
+/TNFa
+) and likewise few single IFN-c-producing
T cells (,3%). Triple-producing multifunctional T cells have been
shown to correlate better with protective immunity than single-
producing T cells in several disease models [26–28]. It remains to
be confirmed whether such a difference in quality of CD4 memory
T cells could explain the differences in levels of protection
observed in mice immunised with BCG or solely with Ag85B-
TB10.4.
Modest but significant levels of immunity (p,0.05) were also
transferred to normal non-irradiated recipients. The lower level of
immunity was expected since the donor T cells would compete less
well for survival against the dominant in situ host population
[29,30]. Antigen-primed CD4 T cells not only provided
immediate protection, but also conferred immunity in recipients
challenged months after cell transfer – a measure of immunolog-
ical memory. Finally, the investigation showed that persisting
antigen, viable and inert, enhanced the protective immunity
transferred by Mtb-specific CD4 T cells.
The CD45RB
low CD62L
low CD4 T cells used here to transfer
immunity are frequently described as both ‘‘memory’’ cells
responsible for long-lasting immunity and confusingly, ‘‘effector’’
cells – cytokine-producing terminally differentiated lymphocytes
[31]. Paradoxically, the CD45RB
low subset is known to be short-
lived [22,32–34]. It is also known that CD45RB
low CD4 T cells
may return to a resting ‘‘naı ¨ve’’ phenotype (CD45RB
high
CD62L
high) in the absence of stimulation [33–36], a resting T
cell with a long lifespan [22,32–34]. It was critical, therefore, to
show that the Mtb-specific CD4 T cells survived and were not
simply short-lived effector cells. Hence, Mtb-specific T cells were
‘‘parked’’ in recipients in the absence of antigen for 2 mo before
BCG challenge. The mice remained protected showing that the
Mtb-specific population survived. Based on other studies many of
the transferred T cells would have re-expressed the CD45RB
high
molecule associated with a long-lived quiescent state [18,37–39]. It
was argued elsewhere [15] that immunological memory accrues
from the initial clonal expansion, the legacy of which is a high
frequency of long-lived antigen-specific T cells. This concept was
strongly supported by experiments showing that protective




high CD4 T cells (i.e. a naı ¨ve phenotype) from
donors immunised to Mtb from which the mycobacterium had
been destroyed months before [37].
In the present experiments, the number of IFN-c
+ Ag85B-
TB10.4-specific CD4 T cells was poorly correlated with
protection; the levels were at best a crude predictor of transferred
immunity. Other groups also reported that ELISPOT and ICC
values for IFN-c had a poor correlation with protection [40–43].
The reasons for this are not entirely clear. One possibility is that
the traditional ICC and ELISPOT assays may not be identifying
all antigen-specific T cells responsible for memory. The studies by
Mohrs et al [44] indicate that in order for CD4 T cells to synthesise
and release cytokines (effector T cells), ‘‘2-hits’’ with specific
antigen are required – the first to generate cytokine message, the
second to initiate synthesis of the cytokine protein. These 2 antigen
encounters are likely to be separated in time and in tissue location.
Hence, naı ¨ve T cells primed in lymph nodes will only synthesise
Figure 5. Persisting antigen enhances protection. (A) To establish
a potential source of residual antigen (Ag) mice were injected with BCG
or Ag85B-TB10.4, 4 weeks (d -28) before irradiation and cell transfer.
Control recipients received no source of residual Ag (None) and were
irradiated 1 day before cell transfer. CD45RB
low CD4 T cells (3610
6) from
BCG primed/Ag85B-TB10.4 boosted donors (Pr/Boost, solid symbols) or
unprimed CD4 T cells (Naı ¨ve, open symbols) were transferred into
recipients after irradiation on d 0. All recipients were challenged with
BCG 4 weeks later (d 28). (B) Three weeks after challenge spleen cells
were assayed for BCG CFUs. Each point represents a single recipient.
Horizontal bars are means of 4 recipients/group. ** p,0.01.
doi:10.1371/journal.pone.0008272.g005
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of infection. The current assays, which stimulate T cells in vitro
(2nd hit), will only induce cytokine production in those T cells that
have already been primed. Importantly, many of the CD4 T cells
initially primed following immunisation may fail to find antigen a
second time and may therefore return to a resting state. A change
from CD45RB
low to CD45RB
high following transfer was con-
firmed in the present study (unpublished observations; DD, EBB).
Such cells become phenotypically and functionally indistinguish-
able from naı ¨ve T cells [35,39]. This memory population would
not be detected by current in vitro assays. Furthermore, as
mentioned earlier, multifunctional CD4 T cells appear to be
more reliable indicators of protective immunity than assays that
screen for IFN-c alone [26–28].
The role of persisting antigen in maintaining CD4 T cell
memory remains a contentious issue [16,45,46]. Evidence
supporting a vital role for residual antigen continues to accumulate
[47–50]. The numbers of successful live vaccines that provide
long-lasting protection (e.g. smallpox, measles, mumps, rubella,
polio and others) is also consistent with a role for persisting
antigen. The present studies explored two different types of
residual antigen – a live source that could replicate (BCG) or an
inert protein that could only decline with time (Ag85B-TB10.4).
Both types of residual antigen were equally effective in enhancing
protective immunity. We can only surmise that relevant epitopes
from both the viable and non-viable sources were available to Mtb-
specific CD4 T cells in vivo. In addition, given that the size of the
memory response appears to be determined by the number of
antigen-specific T cells [24], the amount of antigen presented was
probably not the limiting factor. The enhancing effect of live BCG
was consistent with earlier work. Fifty years ago it was reported
that live but not killed BCG induced lasting protective immunity
[51]. More recently, Olsen et al. [52] found that immunity
measured in the spleen declined in BCG-immunised mice when
the microorganism was cleared by antibiotic therapy. The
augmented protection associated with residual recombinant
vaccine was more surprising and implies a significant retention
of specific antigenic epitopes, in all probability related to the
delivery vehicle. Whether or not a non-viable vaccine will
maintain memory may, therefore, depend on the nature of the
adjuvant. Recent evidence indicates that the cationic liposome
adjuvant DDA/TDB, used here, persists for an extended period at
the injection site (D. Christensen, personal communication) and
maintains immunological memory very effectively [13]. The
success of non-viable vaccines may ultimately hinge on advances
made in developing new delivery systems that are safe for use in
humans and that release antigen slowly from a depot.
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